Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...

Of course, some of the rally’s nothing more than the left-behind stocks playing catch up. The drug stocks had a rare day in ...

Bristol-Myers Squibb announced promising progress on its Phase 2 Alzheimer’s clinical trial of BMS-986446, an experimental ...

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

If your physician prescribes a new branded drug, though, you and your insurance company have few options. Patent-protected ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Bristol-Myers Squibb terminated a real-world, non-interventional study on Ozanimod, targeting moderate-to-severe ulcerative ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...